Global and United States Direct Oral Anticoagulant Market Report & Forecast 2022-2028

SKU ID : QYR-20786506 | Publishing Date : 25-Apr-2022

Direct Oral Anticoagulants are rapid and short acting agents which have relatively low bleeding risks and overall safety. Direct oral anticoagulants are alternative choice for blood clot treatment in selected patients.
Market Analysis and Insights: Global and United States Direct Oral Anticoagulant Market
This report focuses on global and United States Direct Oral Anticoagulant market, also covers the segmentation data of other regions in regional level and county level.
Due to the COVID-19 pandemic, the global Direct Oral Anticoagulant market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, by Type, Apixaban accounting for % of the Direct Oral Anticoagulant global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Application, Hospitals Pharmacies was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.
In United States the Direct Oral Anticoagulant market size is expected to grow from US$ million in 2021 to US$ million by 2028, at a CAGR of % during the forecast period.
Global Direct Oral Anticoagulant Scope and Market Size
Direct Oral Anticoagulant market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Direct Oral Anticoagulant market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Direct Oral Anticoagulant market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Apixaban
Dabigatran
Rivaroxaban
Edoxaban
Segment by Application
Hospitals Pharmacies
Drug Stores
Online Pharmacies
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Bristol-Meyers Squibb Co
Pfizer Inc.
Boehringer Ingelheim Pharmaceuticals, Inc
Janssen Pharmaceuticals, Inc.
Bayer AG
Teva Pharmaceutical Industries Ltd
Pab Organics Private Limited
Daiichi Sankyo Company, Limited

Frequently Asked Questions

This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
  • By product type
  • By End User/Applications
  • By Technology
  • By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
market Reports market Reports